3,6-dioxa-8-hydroxyoctyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside | 126765-19-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3,6-dioxa-8-hydroxyoctyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside
• 英文别名: [(2R,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]oxan-2-yl]methyl acetate
• CAS: 126765-19-3
• 化学式: C₂₀H₃₂O₁₃
• 分子量: 480.466
• InChiKey: VKJPEZNPYMNCSH-OUUBHVDSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.89
• 重原子数：
  33.0
• 可旋转键数：
  14.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  162.35
• 氢给体数：
  1.0
• 氢受体数：
  13.0

反应信息

• 作为反应物：
  描述：

  3,6-dioxa-8-hydroxyoctyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside 在 2,2,6,6-四甲基哌啶氧化物 、 碘苯二乙酸 作用下， 以 水 、 乙腈 为溶剂， 以97 %的产率得到2-(((2R,3R,45,55,6R)-3,4,5-triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-yl)oxy)acetic acid
  参考文献：
  名称：

  [EN] GLUCOSE SENSITIVE INSULIN DERIVATIVES AND USES THEREOF
  [FR] DÉRIVÉS D'INSULINE SENSIBLES AU GLUCOSE ET LEURS UTILISATIONS

  摘要：

  The present invention relates to novel insulin derivatives and their use in the treatment or prevention of medical conditions relating to diabetes. The insulin derivatives are glucose sensitive and display glucose-sensitive insulin receptor binding. The invention also relates to novel intermediates. Finally, the invention provides a pharmaceutical composition comprising the insulin derivatives of the invention and the use of such a composition in the treatment or prevention of medical conditions relating to diabetes.

  公开号：

  WO2023144240A1
• 作为产物：
  描述：

  β-D-葡萄糖五乙酸酯 在 氢溴酸 、 溶剂黄146 、 silver carbonate 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 6.0h， 生成 3,6-dioxa-8-hydroxyoctyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside
  参考文献：
  名称：

  [EN] GLUCOSE SENSITIVE INSULIN DERIVATIVES AND USES THEREOF
  [FR] DÉRIVÉS D'INSULINE SENSIBLES AU GLUCOSE ET LEURS UTILISATIONS

  摘要：

  The present invention relates to novel insulin derivatives and their use in the treatment or prevention of medical conditions relating to diabetes. The insulin derivatives are glucose sensitive and display glucose-sensitive insulin receptor binding. The invention also relates to novel intermediates. Finally, the invention provides a pharmaceutical composition comprising the insulin derivatives of the invention and the use of such a composition in the treatment or prevention of medical conditions relating to diabetes.

  公开号：

  WO2023144240A1

文献信息

• Szurmai, Zoltan; Szabo, Lajos; Liptak, Andras, Acta Chimica Hungarica, 1989, vol. 126, # 2, p. 259 - 270
  作者：Szurmai, Zoltan、Szabo, Lajos、Liptak, Andras

  DOI：——

  日期：——
• SZURMAI, ZOLTAN;SZABO, LAJOS;LIPTAK, ANDRAS, ACTA CHIM. HUNG., 126,(1989) N, C. 259-269
  作者：SZURMAI, ZOLTAN、SZABO, LAJOS、LIPTAK, ANDRAS

  DOI：——

  日期：——